Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation & Amortization (2019 - 2025)

Historic Accumulated Depreciation & Amortization for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $8.7 million.

  • Nurix Therapeutics' Accumulated Depreciation & Amortization fell 620.3% to $8.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $8.7 million, marking a year-over-year decrease of 620.3%. This contributed to the annual value of $8.7 million for FY2025, which is 620.3% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Accumulated Depreciation & Amortization is $8.7 million, which was down 620.3% from $40.7 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Accumulated Depreciation & Amortization peaked at $40.7 million during Q3 2025, and registered a low of $1.8 million during Q1 2023.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $15.1 million (2021), whereas its average is $17.8 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 8884.57% in 2023, then surged by 169775.06% in 2025.
  • Nurix Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $2.8 million in 2021, then skyrocketed by 91.04% to $5.3 million in 2022, then soared by 40.83% to $7.5 million in 2023, then increased by 23.7% to $9.3 million in 2024, then decreased by 6.2% to $8.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $8.7 million for Q4 2025, versus $40.7 million for Q3 2025 and $38.7 million for Q2 2025.